Search

Your search keyword '"Sanguineti G"' showing total 778 results
Start Over Author "Sanguineti G"
778 results on '"Sanguineti G"'

1. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Author

Lacas, Benjamin, Carmel, Alexandra, Landais, Cécile, Wong, Stuart J, Licitra, Lisa, Tobias, Jeffrey S, Burtness, Barbara, Ghi, Maria Grazia, Cohen, Ezra EW, Grau, Cai, Wolf, Gregory, Hitt, Ricardo, Corvò, Renzo, Budach, Volker, Kumar, Shaleen, Laskar, Sarbani Ghosh, Mazeron, Jean-Jacques, Zhong, Lai-Ping, Dobrowsky, Werner, Ghadjar, Pirus, Fallai, Carlo, Zakotnik, Branko, Sharma, Atul, Bensadoun, René-Jean, Redda, Maria Grazia Ruo, Racadot, Séverine, Fountzilas, George, Brizel, David, Rovea, Paolo, Argiris, Athanassios, Nagy, Zoltán Takácsi, Lee, Ju-Whei, Fortpied, Catherine, Harris, Jonathan, Bourhis, Jean, Aupérin, Anne, Blanchard, Pierre, Pignon, Jean-Pierre, Group, MACH-NC Collaborative, Adelstein, DJ, Alfonsi, M, Belkacemi, Y, Bar-Ad, V, Bernier, J, Bratland, Å, Calais, G, Campbell, B, Caudell, J, Chabaud, S, Chamorey, E, Chaukar, D, Choi, KN, Choussy, O, Collette, L, Cruz, JJ, Dani, C, Dauzier, E, Forastiere, AA, Garaud, P, Gregoire, V, Hackshaw, A, Haddad, E, Haffty, BG, Hansen, A, Hayoz, S, Horiot, JC, Jeremic, B, Karrison, TG, Langendijk, JA, Lapeyre, M, Lartigau, E, Leong, T, Le, QT, Lee, PPY, Lewin, F, Lin, A, Lopes, A, Mehta, S, Moon, J, Moyal, E, Occéan, BV, Olmi, P, Orecchia, R, O'Sullivan, B, Overgaard, J, Petit, C, Quon, H, Sanguineti, G, Satar, T, Simes, J, Simon, C, Sire, C, Staar, S, Stromberger, C, Strojan, P, Temam, S, Thomson, D, Timochenko, A, Torri, V, and Tseroni, V

Subjects
Cancer, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Chemotherapy, Adjuvant, Head and Neck Neoplasms, Humans, Induction Chemotherapy, Randomized Controlled Trials as Topic, Meta-analysis, Review, Individual Patient Data, Randomised Clinical Trials, Chemotherapy, Radiotherapy, Head and Neck Cancer, MACH-NC Collaborative Group, Other Physical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Background and purposeThe Meta-Analysis of Chemotherapy in squamous cell Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) improved overall survival (OS) in patients without distant metastasis. We report the updated results.Materials and methodsPublished or unpublished randomized trials including patients with non-metastatic carcinoma randomized between 1965 and 2016 and comparing curative loco-regional treatment (LRT) to LRT + CT or adding another timing of CT to LRT + CT (main question), or comparing induction CT + radiotherapy to radiotherapy + concomitant (or alternating) CT (secondary question) were eligible. Individual patient data were collected and combined using a fixed-effect model. OS was the main endpoint.ResultsFor the main question, 101 trials (18951 patients, median follow-up of 6.5 years) were analyzed. For both questions, there were 16 new (2767 patients) and 11 updated trials. Around 90% of the patients had stage III or IV disease. Interaction between treatment effect on OS and the timing of CT was significant (p

Published
2021

2. Learning from NATO Biomarker Research for Humans

Author

Giovanetti, A., Marconi, R., Bartoleschi, C., Pardini, M. C., Turchi, R., Awad, N., Sanguineti, G., Pinnarò, P., Tortolici, F., Rufini, S., Canfora, M., Strigari, L., Wood, Michael D., editor, Mothersill, Carmel E., editor, Tsakanova, Gohar, editor, Cresswell, Tom, editor, and Woloschak, Gayle E., editor

Published
2022
Full Text
View/download PDF

4. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Author

Adelstein, D.J., Agarwal, J., Alfonsi, M., Argiris, A., Aupérin, A., Bacigalupo, A., Bar-Ad, V., Bartelink, H., Beadle, B., Belkacemi, Y., Bensadoun, R.J., Bernier, J., Blanchard, P., Bourhis, J., Bratland, Å., Brizel, D., Budach, V., Budach, W., Burtness, B., Calais, G., Campbell, B., Caudell, J., Chabaud, S., Chamorey, E., Chaukar, D., Cheugoua-Zanetsie, M., Cho, K.H., Choussy, O., Cruz Hernandez, J.J., Denham, J.W., Dobrowsky, W., Dominello, M.M, Driessen, C.M.L., Fallai, C., Forastiere, A.A., Fortpied, C., Fountzilas, G., Garaud, P., Garden, A.S., Gery, B., Ghadjar, P., Ghi, M.G., Ghosh Laskar, S., Graff-Cailleaud, P., Grau, C., Gregoire, V., Hackshaw, A., Haddad, E, Haffty, B.G., Hansen, A., Hay, J.H., Hayoz, S., Horiot, J.C., Hitt, R., Jeremic, B., Johansen, J., Jones, C., Julieron, M., Kristensen, C.A., Kumar, S., Lacas, B., Langendijk, J.A., Lapeyre, M., Lartigau, E., Licitra, L., Le, Q.T., Lee, J.W., Lee, P., Lewin, F., Li, Y., Lopes, A., Lotayef, M., Maciejewski, B., Mazeron, J.J., Mehta, S., Michalski, W., Moon, J., Moon, S.H., Moyal, E., Nankivell, M., Nilsson, P., Olmi, P., Orecchia, R., O'Sullivan, B., Overgaard, J., Parmar, M.K.B., Petit, C., Pignon, J.P., Pointreau, Y., Posner, M.R., Poulsen, M.G., Quon, H., Racadot, S., Rosenthal, D.I., Rovea, P., Ruo Redda, M.G., Sanguineti, G., Shenouda, G., Simes, J., Sharma, A., Simon, C., Sire, C., Skladowski, K., Spencer, S., Staar, S., Strojan, P., Stromberger, C., Suwinski, R., Szutkowski, Z., Takácsi-Nagy, Z., Tao, Y.G., Temam, S., Thomson, D., Tobias, J.S., Torres-Saavedra, P., Torri, V., Tripcony, L., Trotti, A., Tseroni, V., van Herpen, C., van Tinteren, H., Vermorken, J., Viegas, C.M.P., Vokes, E.E., Waldron, J., Wernecke, K.D, Widder, J., Wolf, G.T., Wong, S.J., Wu, J.S., Yamazaki, H., Zaktonik, B., Zackrisson, B., Zhong, L.P., Petit, Claire, Lacas, Benjamin, Pignon, Jean-Pierre, Le, Quynh Thu, Grégoire, Vincent, Grau, Cai, Hackshaw, Allan, Zackrisson, Björn, Parmar, Mahesh K B, Lee, Ju-Whei, Ghi, Maria Grazia, Sanguineti, Giuseppe, Temam, Stéphane, Cheugoua-Zanetsie, Maurice, O'Sullivan, Brian, Posner, Marshall R, Vokes, Everett E, Cruz Hernandez, Juan J, Szutkowski, Zbigniew, Lartigau, Eric, Budach, Volker, Suwiński, Rafal, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Jeremic, Branislav, Simes, John, Zhong, Lai-Ping, Overgaard, Jens, Fortpied, Catherine, Torres-Saavedra, Pedro, Bourhis, Jean, Aupérin, Anne, and Blanchard, Pierre

Published
2021
Full Text
View/download PDF

5. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Author

Adelstein, D.J., Alfonsi, M., Belkacemi, Y., Bar-Ad, V., Bernier, J., Bratland, Å., Calais, G., Campbell, B., Caudell, J., Chabaud, S., Chamorey, E., Chaukar, D., Choi, K.N., Choussy, O., Collette, L., Cruz, J.J., Dani, C., Dauzier, E., Forastiere, A.A., Garaud, P., Gregoire, V., Hackshaw, A., Haddad, E., Haffty, B.G., Hansen, A., Hayoz, S., Horiot, J.C., Jeremic, B., Karrison, T.G., Langendijk, J.A., Lapeyre, M., Lartigau, E., Leong, T., Le, Q.T., Lee, P.P.Y., Lewin, F., Lin, A., Lopes, A., Mehta, S., Moon, J., Moyal, E., Occéan, B.V., Olmi, P., Orecchia, R., O'Sullivan, B., Overgaard, J., Petit, C., Quon, H., Sanguineti, G., Satar, T., Simes, J., Simon, C., Sire, C., Staar, S., Stromberger, C., Strojan, P., Temam, S., Thomson, D., Timochenko, A., Torri, V., Tseroni, V., Vermorken, J., Vokes, E.E., Waldron, J., Wernecke, K.D., Widder, J., Zackrisson, B., Lacas, Benjamin, Carmel, Alexandra, Landais, Cécile, Wong, Stuart J., Licitra, Lisa, Tobias, Jeffrey S., Burtness, Barbara, Ghi, Maria Grazia, Cohen, Ezra E.W., Grau, Cai, Wolf, Gregory, Hitt, Ricardo, Corvò, Renzo, Budach, Volker, Kumar, Shaleen, Laskar, Sarbani Ghosh, Mazeron, Jean-Jacques, Zhong, Lai-Ping, Dobrowsky, Werner, Ghadjar, Pirus, Fallai, Carlo, Zakotnik, Branko, Sharma, Atul, Bensadoun, René-Jean, Ruo Redda, Maria Grazia, Racadot, Séverine, Fountzilas, George, Brizel, David, Rovea, Paolo, Argiris, Athanassios, Nagy, Zoltán Takácsi, Lee, Ju-Whei, Fortpied, Catherine, Harris, Jonathan, Bourhis, Jean, Aupérin, Anne, Blanchard, Pierre, and Pignon, Jean-Pierre

Published
2021
Full Text
View/download PDF

6. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author

Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., Vici P., Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., and Vici P.

Abstract

Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available. Methods: We carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recruited. We primarily focused on treatment tolerability, with toxicity being reported as potential cause of treatment discontinuation. Secondarily, we assessed effectiveness in the overall study population and in a subset having a minimum follow-up of 2 years. Results: Overall, 270 patients were retrospectively identified. The 50.4% of the patients had residual node positive disease, 7.8% and 81.9% had large or G3 residual tumor, respectively, and 80.4% a Ki-67 >20%. Toxicity-related treatment discontinuation was observed only in 10.4% of the patients. In the whole population, at a median follow-up of 15 months, 2-year disease-free survival was 62%, 2 and 3-year overall survival 84.0% and 76.2%, respectively. In 129 patients with a median follow-up of 25 months, 2-year disease-free survival was 43.4%, 2 and 3-year overall survival 78.0% and 70.8%, respectively. Six or more cycles of capecitabine were associated with more favourable outcomes compared with less than six cycles. Conclusion: The CaRe study shows an unexpectedly good tolerance of adjuvant capecitabine in a real-world setting, although effectiveness appears to be lower than that observed in the CREATE-X study. Methodological differences between the two studies impose significant limits to comparability concerning ef

Published
2023

8. WORSENING OF 2-YEAR PATIENT-REPORTED INTESTINAL FUNCTIONALITY AFTER RADIOTHERAPY FOR PROSTATE CANCER INCLUDING PELVIC NODE IRRADIATION

Author

Pavarini, M., primary, Sanguineti, G., additional, Munoz, F., additional, Magli, A., additional, Cante, D., additional, Garibaldi, E., additional, Gebbia, A., additional, Chiorda, B. Noris, additional, Girelli, G., additional, Villa, E., additional, Faiella, A., additional, Waskiewicz, J.M., additional, Avuzzi, B., additional, Pastorino, A., additional, Moretti, E., additional, Rago, L., additional, Statuto, T., additional, Rancati, T., additional, Valdagni, R., additional, Vavassori, V.L., additional, Gatti, M., additional, Di Muzio, N.G., additional, Cozzarini, C., additional, and Fiorino, C., additional

Published
2023
Full Text
View/download PDF

9. ASSOCIATION OF PERSISTENT URINARY SYMPTOMS WITH QUALITY OF LIFE AFTER PROSTATE CANCER RADIOTHERAPY

Author

Spampinato, S., primary, Waskiewicz, J.M., additional, Avuzzi, B., additional, Garibaldi, E., additional, Faiella, A., additional, Villa, E., additional, Magli, A., additional, Cante, D., additional, Girelli, G., additional, Gatti, M., additional, Chiorda, B. Noris, additional, Rago, L., additional, Ferrari, P., additional, Piva, C., additional, Pavarini, M., additional, Rancati, T., additional, Valdagni, R., additional, Vavassori, V., additional, Munoz, F., additional, Sanguineti, G., additional, Di Muzio, N., additional, Kirchheiner, K., additional, Fiorino, C., additional, and Cozzarini, C., additional

Published
2023
Full Text
View/download PDF

10. INFLUENCE OF THE 4D ROBUST PLANNING APPROACH ON THE COMPARISON BETWEEN PHOTON AND PROTON FOR THE TREATMENT OF STAGE III LUNG CANCER: A DOSIMETRIC AND RADIOBIOLOGICAL STUDY

Author

Widesott, L., primary, Landoni, V., additional, Dionisi, F., additional, Siniscalchi, B., additional, Nardangeli, A., additional, Fracchiolla, F., additional, Turkaj, A., additional, Soriani, A., additional, Righetto, R., additional, Goanta, L., additional, Farace, P., additional, Petrongari, M.G., additional, Trianni, A., additional, Amelio, D., additional, Lorentini, S., additional, Cianchetti, M., additional, and Sanguineti, G., additional

Published
2023
Full Text
View/download PDF

15. MO-0220 Two-year impact of bowel symptoms on HRQoL after RT for prostate cancer with pelvic node irradiation

Author

Pavarini, M., primary, Rago, L., additional, Munoz, F., additional, Magli, A., additional, Cante, D., additional, Girelli, G., additional, Bresolin, A., additional, Noris Chiorda, B., additional, Waskiewicz, J.M., additional, Avuzzi, B., additional, Garibaldi, E., additional, Faiella, A., additional, Villa, E., additional, Ferrari, P., additional, Ferella, L., additional, Piva, C., additional, Statuto, T., additional, Gatti, M., additional, Rancati, T., additional, Valdagni, R., additional, Vavassori, V.L., additional, Sanguineti, G., additional, Di Muzio, N.G., additional, Fiorino, C., additional, and Cozzarini, C., additional

Published
2023
Full Text
View/download PDF

18. PO-1483 Persistent urinary symptoms and long-term quality of life after prostate cancer radiotherapy

Author

Spampinato, S., primary, Waskiewicz, J.M., additional, Avuzzi, B., additional, Garibaldi, E., additional, Faiella, A., additional, Villa, E., additional, Magli, A., additional, Cante, D., additional, Girelli, G., additional, Gatti, M., additional, Ferella, L., additional, Noris Chiorda, B., additional, Rago, L., additional, Ferrari, P., additional, Piva, C., additional, Maddalena, P., additional, Tiziana, R., additional, Valdagni, R., additional, Vavassori, V., additional, Munoz, F., additional, Sanguineti, G., additional, Di Muzio, N., additional, Kirchheiner, K., additional, Fiorino, C., additional, and Cozzarini, C., additional

Published
2023
Full Text
View/download PDF

19. Current management and future challenges in salivary glands cancer

Author

Locati, L, Ferrarotto, R, Licitra, L, Benazzo, M, Preda, L, Farina, D, Gatta, G, Lombardi, D, Nicolai, P, Vander Poorten, V, Chua, M, Vischioni, B, Sanguineti, G, Morbini, P, Fonseca, I, Sozzi, D, Merlotti, A, Orlandi, E, Locati, L, Ferrarotto, R, Licitra, L, Benazzo, M, Preda, L, Farina, D, Gatta, G, Lombardi, D, Nicolai, P, Vander Poorten, V, Chua, M, Vischioni, B, Sanguineti, G, Morbini, P, Fonseca, I, Sozzi, D, Merlotti, A, and Orlandi, E

Abstract

Salivary gland cancers (SGCs) are rare, accounting for less than 5% of all malignancies of the head and neck region, and are morphologically heterogeneous. The diagnosis is mainly based on histology, with the complementary aid of molecular profiling, which is helpful in recognizing some poorly differentiated, borderline, or atypical lesions. Instrumental imaging defines the diagnosis, representing a remarkable tool in the treatment plan. Ultrasound and magnetic resonance are the most common procedures used to describe the primary tumour. The treatment of SGCs is multimodal and consists of surgery, radiotherapy, and systemic therapy; each treatment plan is, however, featured on the patient and disease’s characteristics. On 24 June 2022, in the meeting “Current management and future challenges in salivary gland cancers” many experts in this field discussed the state of the art of SGCs research, the future challenges and developments. After the meeting, the same pool of experts maintained close contact to keep these data further updated in the conference proceedings presented here. This review collects the insights and suggestions that emerged from the discussion during and after the meeting per se.

Published
2023

20. PD-01.48 - WORSENING OF 2-YEAR PATIENT-REPORTED INTESTINAL FUNCTIONALITY AFTER RADIOTHERAPY FOR PROSTATE CANCER INCLUDING PELVIC NODE IRRADIATION

Author

Pavarini, M., Sanguineti, G., Munoz, F., Magli, A., Cante, D., Garibaldi, E., Gebbia, A., Chiorda, B. Noris, Girelli, G., Villa, E., Faiella, A., Waskiewicz, J.M., Avuzzi, B., Pastorino, A., Moretti, E., Rago, L., Statuto, T., Rancati, T., Valdagni, R., Vavassori, V.L., Gatti, M., Di Muzio, N.G., Cozzarini, C., and Fiorino, C.

Published
2023
Full Text
View/download PDF

28. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

Author

Pizzuti, L, Barba, M, Mazzotta, M, Krasniqi, E, Maugeri-Sacca, M, Gamucci, T, Berardi, R, Livi, L, Ficorella, C, Natoli, C, Cortesi, E, Generali, D, La Verde, N, Cassano, A, Bria, E, Moscetti, L, Michelotti, A, Adamo, V, Zamagni, C, Tonini, G, Sergi, D, Marinelli, D, Paoletti, G, Tomao, S, Botticelli, A, Marchetti, P, Tinari, N, Grassadonia, A, Valerio, M, Mirabelli, R, Fabbri, M, D'Ostilio, N, Veltri, E, Corsi, D, Garrone, O, Paris, I, Sarobba, G, Meattini, I, Pistelli, M, Giotta, F, Lorusso, V, Garufi, C, Russo, A, Cazzaniga, M, Del Medico, P, Roselli, M, Vaccaro, A, Perracchio, L, di Benedetto, A, Daralioti, T, Sperduti, I, De Maria, R, Di Leo, A, Sanguineti, G, Ciliberto, G, Vici, P, Pizzuti L., Barba M., Mazzotta M., Krasniqi E., Maugeri-Sacca M., Gamucci T., Berardi R., Livi L., Ficorella C., Natoli C., Cortesi E., Generali D., La Verde N., Cassano A., Bria E., Moscetti L., Michelotti A., Adamo V., Zamagni C., Tonini G., Sergi D., Marinelli D., Paoletti G., Tomao S., Botticelli A., Marchetti P., Tinari N., Grassadonia A., Valerio M. R., Mirabelli R., Fabbri M. A., D'Ostilio N., Veltri E., Corsi D., Garrone O., Paris I., Sarobba G., Meattini I., Pistelli M., Giotta F., Lorusso V., Garufi C., Russo A., Cazzaniga M., Del Medico P., Roselli M., Vaccaro A., Perracchio L., di Benedetto A., Daralioti T., Sperduti I., De Maria R., Di Leo A., Sanguineti G., Ciliberto G., Vici P., Pizzuti, L, Barba, M, Mazzotta, M, Krasniqi, E, Maugeri-Sacca, M, Gamucci, T, Berardi, R, Livi, L, Ficorella, C, Natoli, C, Cortesi, E, Generali, D, La Verde, N, Cassano, A, Bria, E, Moscetti, L, Michelotti, A, Adamo, V, Zamagni, C, Tonini, G, Sergi, D, Marinelli, D, Paoletti, G, Tomao, S, Botticelli, A, Marchetti, P, Tinari, N, Grassadonia, A, Valerio, M, Mirabelli, R, Fabbri, M, D'Ostilio, N, Veltri, E, Corsi, D, Garrone, O, Paris, I, Sarobba, G, Meattini, I, Pistelli, M, Giotta, F, Lorusso, V, Garufi, C, Russo, A, Cazzaniga, M, Del Medico, P, Roselli, M, Vaccaro, A, Perracchio, L, di Benedetto, A, Daralioti, T, Sperduti, I, De Maria, R, Di Leo, A, Sanguineti, G, Ciliberto, G, Vici, P, Pizzuti L., Barba M., Mazzotta M., Krasniqi E., Maugeri-Sacca M., Gamucci T., Berardi R., Livi L., Ficorella C., Natoli C., Cortesi E., Generali D., La Verde N., Cassano A., Bria E., Moscetti L., Michelotti A., Adamo V., Zamagni C., Tonini G., Sergi D., Marinelli D., Paoletti G., Tomao S., Botticelli A., Marchetti P., Tinari N., Grassadonia A., Valerio M. R., Mirabelli R., Fabbri M. A., D'Ostilio N., Veltri E., Corsi D., Garrone O., Paris I., Sarobba G., Meattini I., Pistelli M., Giotta F., Lorusso V., Garufi C., Russo A., Cazzaniga M., Del Medico P., Roselli M., Vaccaro A., Perracchio L., di Benedetto A., Daralioti T., Sperduti I., De Maria R., Di Leo A., Sanguineti G., Ciliberto G., and Vici P.

Abstract

In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. Data of patients affected by HER2-positive mBC, treated with pertuzumab and/or trastuzumab-emtansine (T-DM1) in a real-world setting at 45 Italian cancer centers were retrospectively collected and analyzed. From 2003 to 2017, 491 HER2‐positive mBC patients were included. Of these, 102 (20.7%) had been initially diagnosed as HER2-negative early BC. Estrogen and/or progesterone receptor were more expressed in patients with HER2-discordance compared to patients with HER2-concordant status (p < 0.0001 and p = 0.006, respectively). HER2-discordant tumors were characterized also by a lower rate of brain metastases (p = 0.01) and a longer disease free interval (p < 0.0001). Median overall survival was longer, although not statistically significant, in the subgroup of patients with HER2-discordant cancer with respect to patients with HER2-concordant status (140 vs 78 months, p = 0.07). Our findings suggest that patients with HER2-positive mBC with discordant HER2 status in early BC may have different clinical, biological and prognostic behavior compared to HER2-concordant patients.

Published
2021

29. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Author

Bon, G, Pizzuti, L, Laquintana, V, Loria, R, Porru, M, Marchio, C, Krasniqi, E, Barba, M, Maugeri-Sacca, M, Gamucci, T, Berardi, R, Livi, L, Ficorella, C, Natoli, C, Cortesi, E, Generali, D, La Verde, N, Cassano, A, Bria, E, Moscetti, L, Michelotti, A, Adamo, V, Zamagni, C, Tonini, G, Barchiesi, G, Mazzotta, M, Marinelli, D, Tomao, S, Marchetti, P, Valerio, M, Mirabelli, R, Russo, A, Fabbri, M, D'Ostilio, N, Veltri, E, Corsi, D, Garrone, O, Paris, I, Sarobba, G, Giotta, F, Garufi, C, Cazzaniga, M, Del Medico, P, Roselli, M, Sanguineti, G, Sperduti, I, Sapino, A, De Maria, R, Leonetti, C, Di Leo, A, Ciliberto, G, Falcioni, R, Vici, P, Bon G., Pizzuti L., Laquintana V., Loria R., Porru M., Marchio C., Krasniqi E., Barba M., Maugeri-Sacca M., Gamucci T., Berardi R., Livi L., Ficorella C., Natoli C., Cortesi E., Generali D., La Verde N., Cassano A., Bria E., Moscetti L., Michelotti A., Adamo V., Zamagni C., Tonini G., Barchiesi G., Mazzotta M., Marinelli D., Tomao S., Marchetti P., Valerio M. R., Mirabelli R., Russo A., Fabbri M. A., D'Ostilio N., Veltri E., Corsi D., Garrone O., Paris I., Sarobba G., Giotta F., Garufi C., Cazzaniga M., Del Medico P., Roselli M., Sanguineti G., Sperduti I., Sapino A., De Maria R., Leonetti C., Di Leo A., Ciliberto G., Falcioni R., Vici P., Bon, G, Pizzuti, L, Laquintana, V, Loria, R, Porru, M, Marchio, C, Krasniqi, E, Barba, M, Maugeri-Sacca, M, Gamucci, T, Berardi, R, Livi, L, Ficorella, C, Natoli, C, Cortesi, E, Generali, D, La Verde, N, Cassano, A, Bria, E, Moscetti, L, Michelotti, A, Adamo, V, Zamagni, C, Tonini, G, Barchiesi, G, Mazzotta, M, Marinelli, D, Tomao, S, Marchetti, P, Valerio, M, Mirabelli, R, Russo, A, Fabbri, M, D'Ostilio, N, Veltri, E, Corsi, D, Garrone, O, Paris, I, Sarobba, G, Giotta, F, Garufi, C, Cazzaniga, M, Del Medico, P, Roselli, M, Sanguineti, G, Sperduti, I, Sapino, A, De Maria, R, Leonetti, C, Di Leo, A, Ciliberto, G, Falcioni, R, Vici, P, Bon G., Pizzuti L., Laquintana V., Loria R., Porru M., Marchio C., Krasniqi E., Barba M., Maugeri-Sacca M., Gamucci T., Berardi R., Livi L., Ficorella C., Natoli C., Cortesi E., Generali D., La Verde N., Cassano A., Bria E., Moscetti L., Michelotti A., Adamo V., Zamagni C., Tonini G., Barchiesi G., Mazzotta M., Marinelli D., Tomao S., Marchetti P., Valerio M. R., Mirabelli R., Russo A., Fabbri M. A., D'Ostilio N., Veltri E., Corsi D., Garrone O., Paris I., Sarobba G., Giotta F., Garufi C., Cazzaniga M., Del Medico P., Roselli M., Sanguineti G., Sperduti I., Sapino A., De Maria R., Leonetti C., Di Leo A., Ciliberto G., Falcioni R., and Vici P.

Abstract

Background: HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to different drugs sequences including pertuzumab and T-DM1 in HER2 positive cell lines. Methods: The biology of HER2 was investigated in vitro through sequential exposure of resistant HER2 + breast cancer cell lines to trastuzumab, pertuzumab, and their combination. In vitro experiments were paralleled by the analysis of data from 555 HER2 + ABC patients treated with T-DM1 and evaluation of T-DM1 efficacy in the 371 patients who received it in second line. Survival estimates were graphically displayed in Kaplan Meier curves, compared by log rank test and, when possibile, confirmed in multivariate models. Results: We herein show evidence of lower activity of T-DM1 in two HER2+ breast cancer cell lines resistant to trastuzumab+pertuzumab, as compared to trastuzumab-resistant cells. Lower T-DM1 efficacy was associated with a marked reduction of HER2 expression on the cell membrane and its nuclear translocation. HER2 downregulation at the membrane level was confirmed in biopsies of four trastuzumab/pertuzumab-pretreated patients. Among the 371 patients treated with second-line T-DM1, median overall survival (mOS) from diagnosis of advanced disease and median progression-free survival to second-line treatment (mPFS2) were 52 and 6 months in 177 patients who received trastuzumab/pertuzumab in f

Published
2020

30. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

Author

Pizzuti, L, Krasniqi, E, Barchiesi, G, Della Giulia, M, Izzo, F, Sanguineti, G, Marchetti, P, Mazzotta, M, Giusti, R, Botticelli, A, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Iezzi, L, Tomao, S, Tomao, F, Tonini, G, Santini, D, Astone, A, Michelotti, A, De Angelis, C, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Rossi, E, Cazzaniga, M, Moscetti, L, Omarini, C, Piacentini, F, Fabbri, M, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Samaritani, R, Garufi, C, Barni, S, Mirabelli, R, Sarmiento, R, Veltri, E, D'Auria, G, Paris, I, Giotta, F, Lorusso, V, Cardillo, F, Landucci, E, Mauri, M, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Berardi, R, Pistelli, M, Fiorio, E, Cannita, K, Sini, V, D'Ostilio, N, Foglietta, J, Greco, F, Zamagni, C, Garrone, O, Di Cocco, B, Baldini, E, Livi, L, Desideri, I, Meattini, I, Sarobba, G, Del Medico, P, De Tursi, M, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Sperduti, I, Villa, A, Barba, M, Di Leo, A, Vici, P, Pizzuti L., Krasniqi E., Barchiesi G., Della Giulia M., Izzo F., Sanguineti G., Marchetti P., Mazzotta M., Giusti R., Botticelli A., Gamucci T., Natoli C., Grassadonia A., Tinari N., Iezzi L., Tomao S., Tomao F., Tonini G., Santini D., Astone A., Michelotti A., De Angelis C., Mentuccia L., Vaccaro A., Magnolfi E., Gelibter A., Magri V., Cortesi E., D'Onofrio L., Cassano A., Rossi E., Cazzaniga M., Moscetti L., Omarini C., Piacentini F., Fabbri M. A., Scinto A. F., Corsi D., Carbognin L., Bria E., La Verde N., Samaritani R., Garufi C., Barni S., Mirabelli R., Sarmiento R., Veltri E. M., D'Auria G., Paris I., Giotta F., Lorusso V., Cardillo F., Landucci E., Mauri M., Ficorella C., Roselli M., Adamo V., Ricciardi G. R. R., Russo A., Berardi R., Pistelli M., Fiorio E., Cannita K., Sini V., D'Ostilio N., Foglietta J., Greco F., Zamagni C., Garrone O., Di Cocco B., Baldini E., Livi L., Desideri I., Meattini I., Sarobba G., Del Medico P., De Tursi M., Generali D., De Maria R., Risi E., Ciliberto G., Sperduti I., Villa A., Barba M., Di Leo A., Vici P., Pizzuti, L, Krasniqi, E, Barchiesi, G, Della Giulia, M, Izzo, F, Sanguineti, G, Marchetti, P, Mazzotta, M, Giusti, R, Botticelli, A, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Iezzi, L, Tomao, S, Tomao, F, Tonini, G, Santini, D, Astone, A, Michelotti, A, De Angelis, C, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Rossi, E, Cazzaniga, M, Moscetti, L, Omarini, C, Piacentini, F, Fabbri, M, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Samaritani, R, Garufi, C, Barni, S, Mirabelli, R, Sarmiento, R, Veltri, E, D'Auria, G, Paris, I, Giotta, F, Lorusso, V, Cardillo, F, Landucci, E, Mauri, M, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Berardi, R, Pistelli, M, Fiorio, E, Cannita, K, Sini, V, D'Ostilio, N, Foglietta, J, Greco, F, Zamagni, C, Garrone, O, Di Cocco, B, Baldini, E, Livi, L, Desideri, I, Meattini, I, Sarobba, G, Del Medico, P, De Tursi, M, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Sperduti, I, Villa, A, Barba, M, Di Leo, A, Vici, P, Pizzuti L., Krasniqi E., Barchiesi G., Della Giulia M., Izzo F., Sanguineti G., Marchetti P., Mazzotta M., Giusti R., Botticelli A., Gamucci T., Natoli C., Grassadonia A., Tinari N., Iezzi L., Tomao S., Tomao F., Tonini G., Santini D., Astone A., Michelotti A., De Angelis C., Mentuccia L., Vaccaro A., Magnolfi E., Gelibter A., Magri V., Cortesi E., D'Onofrio L., Cassano A., Rossi E., Cazzaniga M., Moscetti L., Omarini C., Piacentini F., Fabbri M. A., Scinto A. F., Corsi D., Carbognin L., Bria E., La Verde N., Samaritani R., Garufi C., Barni S., Mirabelli R., Sarmiento R., Veltri E. M., D'Auria G., Paris I., Giotta F., Lorusso V., Cardillo F., Landucci E., Mauri M., Ficorella C., Roselli M., Adamo V., Ricciardi G. R. R., Russo A., Berardi R., Pistelli M., Fiorio E., Cannita K., Sini V., D'Ostilio N., Foglietta J., Greco F., Zamagni C., Garrone O., Di Cocco B., Baldini E., Livi L., Desideri I., Meattini I., Sarobba G., Del Medico P., De Tursi M., Generali D., De Maria R., Risi E., Ciliberto G., Sperduti I., Villa A., Barba M., Di Leo A., and Vici P.

Abstract

We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression-free survival at first-line (mPFS1) was 12 months. Pertuzumab as first-line conferred longer mPFS1 compared to other first-line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second-line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T-DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing both hormonal receptors (HRs; p = 0.17), while a trend emerged for tumors with one HR (p = 0.05). Conversely, PFS2 gain was significant in HRs-negative tumors (p = 0.04). Median overall survival (mOS) was 74 months, with no significant differences by IHC subtypes. Survival rates at 2 and 3 years in patients treated with T-DM1 in second-line after pertuzumab were significantly lower compared to pertuzumab-naïve patients (p = 0.01). When analyzed by IHC subtype, the outcome was confirmed if both HRs or no HRs were expressed (p = 0.02 and p = 0.006, respectively). Our results confirm that HRs expression impacts the clinical behavior and novel treatment-related outcomes of HER2-positive tumors when treatment sequences are considered. Moreover, multivariate analysis showed that HRs expression had no effect on PFS and OS. Further studies are warranted to confirm our findings and clarify the interplay between HER2 and estrogen receptor pathways in HER2-positive (mbc) patients

Published
2020

32. PD-0415 Pelvic RT in prostate cancer: late intestinal toxicity is modulated by severity of acute symptoms

Author

Gebbia, A., Munoz, F., Magli, A., Cante, D., Garibaldi, E., Noris Chiorda, B., Girelli, G., Villa, E., Faiella, A., Waskiewicz, J.M., Avuzzi, B., Pastorino, A., Moretti, E., Rago, L., Bresolin, A., Bianconi, C., Badenchini, F., Rancati, T., Valdagni, R., Vavassori, V., Gatti, M., Sanguineti, G., Di Muzio, N., Fiorino, C., and Cozzarini, C.

Published
2022
Full Text
View/download PDF

33. OC-0457 Modeling outcome after salvage post-prostatectomy radiotherapy: impact of pelvic nodes irradiation

Author

Olivieri, M., primary, Cozzarini, C., additional, Magli, A., additional, Cante, D., additional, Noris Chiorda, B., additional, Munoz, F., additional, Faiella, A., additional, Olivetta, E., additional, Signor, M.A., additional, Piva, C., additional, Avuzzi, B., additional, Ferella, L., additional, Pastorino, A., additional, Garibaldi, E., additional, Gatti, M., additional, Rago, L., additional, Statuto, T., additional, Broggi, S., additional, Fodor, A., additional, Deantoni, C., additional, Rancati, T., additional, Sanguineti, G., additional, Valdagni, R., additional, Di Muzio, N., additional, and Fiorino, C., additional

Published
2022
Full Text
View/download PDF

34. PD-0414 Trend over time of patient-reported QoL domains after pelvic nodal irradiation for prostate cancer

Author

Faiella, A., primary, Gebbia, A., additional, Villa, E., additional, Waskiewicz, J.M., additional, Magli, A., additional, Avuzzi, B., additional, Garibaldi, E., additional, Cante, D., additional, Girelli, G., additional, Gatti, M., additional, Ferella, L., additional, Noris Chiorda, B., additional, Rago, L., additional, Ferrari, P., additional, Bresolin, A., additional, Piva, C., additional, Badenchini, F., additional, Rancati, T., additional, Valdagni, R., additional, Vavassori, V., additional, Munoz, F., additional, Sanguineti, G., additional, Di Muzio, N., additional, Fiorino, C., additional, and Cozzarini, C., additional

Published
2022
Full Text
View/download PDF

37. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

Author

Pizzuti, L, Giordano, A, Michelotti, A, Mazzotta, M, Natoli, C, Gamucci, T, De Angelis, C, Landucci, E, Diodati, L, Iezzi, L, Mentuccia, L, Fabbri, A, Barba, M, Sanguineti, G, Marchetti, P, Tomao, S, Mariani, L, Paris, I, Lorusso, V, Vallarelli, S, Cassano, A, Airoldi, F, Orlandi, A, Moscetti, L, Sergi, D, Sarobba, M, Tonini, G, Santini, D, Sini, V, Veltri, E, Vaccaro, A, Ferrari, L, De Tursi, M, Tinari, N, Grassadonia, A, Greco, F, Botticelli, A, La Verde, N, Zamagni, C, Rubino, D, Cortesi, E, Magri, V, Pomati, G, Scagnoli, S, Capomolla, E, Kayal, R, Scinto, A, Corsi, D, Cazzaniga, M, Laudadio, L, Forciniti, S, Mancini, M, Carbognin, L, Seminara, P, Barni, S, Samaritani, R, Roselli, M, Portarena, I, Russo, A, Ficorella, C, Cannita, K, Carpano, S, Pistelli, M, Berardi, R, De Maria, R, Sperduti, I, Ciliberto, G, Vici, P, Pizzuti L., Giordano A., Michelotti A., Mazzotta M., Natoli C., Gamucci T., De Angelis C., Landucci E., Diodati L., Iezzi L., Mentuccia L., Fabbri A., Barba M., Sanguineti G., Marchetti P., Tomao S., Mariani L., Paris I., Lorusso V., Vallarelli S., Cassano A., Airoldi F., Orlandi A., Moscetti L., Sergi D., Sarobba M. G., Tonini G., Santini D., Sini V., Veltri E., Vaccaro A., Ferrari L., De Tursi M., Tinari N., Grassadonia A., Greco F., Botticelli A., La Verde N., Zamagni C., Rubino D., Cortesi E., Magri V., Pomati G., Scagnoli S., Capomolla E., Kayal R., Scinto A. F., Corsi D., Cazzaniga M., Laudadio L., Forciniti S., Mancini M., Carbognin L., Seminara P., Barni S., Samaritani R., Roselli M., Portarena I., Russo A., Ficorella C., Cannita K., Carpano S., Pistelli M., Berardi R., De Maria R., Sperduti I., Ciliberto G., Vici P., Pizzuti, L, Giordano, A, Michelotti, A, Mazzotta, M, Natoli, C, Gamucci, T, De Angelis, C, Landucci, E, Diodati, L, Iezzi, L, Mentuccia, L, Fabbri, A, Barba, M, Sanguineti, G, Marchetti, P, Tomao, S, Mariani, L, Paris, I, Lorusso, V, Vallarelli, S, Cassano, A, Airoldi, F, Orlandi, A, Moscetti, L, Sergi, D, Sarobba, M, Tonini, G, Santini, D, Sini, V, Veltri, E, Vaccaro, A, Ferrari, L, De Tursi, M, Tinari, N, Grassadonia, A, Greco, F, Botticelli, A, La Verde, N, Zamagni, C, Rubino, D, Cortesi, E, Magri, V, Pomati, G, Scagnoli, S, Capomolla, E, Kayal, R, Scinto, A, Corsi, D, Cazzaniga, M, Laudadio, L, Forciniti, S, Mancini, M, Carbognin, L, Seminara, P, Barni, S, Samaritani, R, Roselli, M, Portarena, I, Russo, A, Ficorella, C, Cannita, K, Carpano, S, Pistelli, M, Berardi, R, De Maria, R, Sperduti, I, Ciliberto, G, Vici, P, Pizzuti L., Giordano A., Michelotti A., Mazzotta M., Natoli C., Gamucci T., De Angelis C., Landucci E., Diodati L., Iezzi L., Mentuccia L., Fabbri A., Barba M., Sanguineti G., Marchetti P., Tomao S., Mariani L., Paris I., Lorusso V., Vallarelli S., Cassano A., Airoldi F., Orlandi A., Moscetti L., Sergi D., Sarobba M. G., Tonini G., Santini D., Sini V., Veltri E., Vaccaro A., Ferrari L., De Tursi M., Tinari N., Grassadonia A., Greco F., Botticelli A., La Verde N., Zamagni C., Rubino D., Cortesi E., Magri V., Pomati G., Scagnoli S., Capomolla E., Kayal R., Scinto A. F., Corsi D., Cazzaniga M., Laudadio L., Forciniti S., Mancini M., Carbognin L., Seminara P., Barni S., Samaritani R., Roselli M., Portarena I., Russo A., Ficorella C., Cannita K., Carpano S., Pistelli M., Berardi R., De Maria R., Sperduti I., Ciliberto G., and Vici P.

Abstract

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

Published
2019

38. PO-1342 Trends and predictors of worsening at RT end of anxiety and depression during RT for prostate cancer

Author

Cante, D., Avuzzi, B., Waskiewicz, J.M., Faiella, A., Villa, E., Ferella, L., Garibaldi, E., Magli, A., Noris Chiorda, B., Girelli, G., Olivetta, E., Piva, C., Gatti, M., Ferrari, P., Moretti, E., Sanguineti, G., Vavassori, V., Munoz, F., Rancati, T., Badenchini, F., Bresolin, A., Valdagni, R., Di Muzio, N., Fiorino, C., and Cozzarini, C.

Published
2021
Full Text
View/download PDF

40. PD-0769 Patient-reported acute intestinal toxicity and impact on patient QoL after WPRT for prostate cancer

Author

Noris Chiorda, B., Munoz, F., Sanguineti, G., Cante, D., Waskiewicz, J.M., Avuzzi, B., Vavassori, V., Gatti, M., Girelli, G., Magli, A., Pastorino, A., Ferella, L., Faiella, A., Piva, C., Ferrari, P., Villa, E., Farina, B., Moretti, E., Rancati, T., Badenchini, F., Bresolin, A., Valdagni, R., Di Muzio, N., Fiorino, C., and Cozzarini, C.

Published
2021
Full Text
View/download PDF

42. Setting up an Italian end-to-end dosimetric audit for IMRT and VMAT: the experience of the OPRORA project

Author

De Angelis, C., primary, Della Monaca, S., additional, Fattibene, P., additional, Anello, P., additional, Quattrini, M.C., additional, Santavenere, F., additional, Soriani, A., additional, Sanguineti, G., additional, Pimpinella, M., additional, De Coste, V., additional, Arrichiello, C., additional, Ametrano, G., additional, Muto, P., additional, Bresciani, S., additional, Miranti, A., additional, Strigari, L., additional, Strolin, S., additional, and Morganti, A., additional

Published
2021
Full Text
View/download PDF

45. PH-0108 New dose-volume constraints for patient-reported acute bowel toxicity symptoms in whole pelvis IMRT

Author

Bresolin, A., primary, Faiella, A., additional, Garibaldi, E., additional, Munoz, F., additional, Cante, D., additional, Vavassori, V., additional, Waskiewicz, J.M., additional, Girellli, G., additional, Avuzzi, B., additional, Villa, E., additional, Magli, A., additional, Noris Chiorda, B., additional, Gatti, M., additional, Ferella, L., additional, Maggio, A., additional, Landoni, V., additional, Aimonetto, S., additional, Sini, C., additional, Rancati, T., additional, Sanguineti, G., additional, Valdagni, R., additional, Di Muzio, N., additional, Cozzarini, C., additional, and Fiorino, C., additional

Published
2021
Full Text
View/download PDF

46. PO-1345 Symptoms affecting Emotional, Systemic and Social Domains 2 years after RT for prostate cancer

Author

Garibaldi, E., primary, Faiella, A., additional, Villa, E., additional, Magli, A., additional, Cante, D., additional, Avuzzi, B., additional, Waskiewicz, J.M., additional, Ferella, L., additional, Noris Chiorda, B., additional, Girelli, G., additional, Pastorino, A., additional, Piva, C., additional, Gatti, M., additional, Ferrari, P., additional, Maggio, A., additional, Olivetta, E., additional, Sanguineti, G., additional, Vavassori, V., additional, Munoz, F., additional, Rancati, T., additional, Badenchini, F., additional, Bresolin, A., additional, Valdagni, R., additional, Di Muzio, N., additional, Fiorino, C., additional, and Cozzarini, C., additional

Published
2021
Full Text
View/download PDF

47. PO-1354 Time Dependence of PSADT prognostic threshold in men treated with post-prostatectomy salvage RT

Author

Cozzarini, C., primary, Magli, A., additional, Cante, D., additional, Andreoli, L., additional, Pastorino, A., additional, Faiella, A., additional, Fodor, A., additional, Deantoni, C., additional, Zerbetto, F., additional, Tonetto, F., additional, Noris Chiorda, B., additional, Piva, C., additional, Olivetta, E., additional, Avuzzi, B., additional, Gandaglia, G., additional, Fossati, N., additional, Fiorino, C., additional, Sanguineti, G., additional, Valdagni, R., additional, Briganti, A., additional, Montorsi, F., additional, and Di Muzio, N., additional

Published
2021
Full Text
View/download PDF

48. PD-0767 Predictors of urinary incontinence 2 years after RT with different intents for prostate cancer

Author

Cozzarini, C., primary, Sanguineti, G., additional, Vavassori, V., additional, Munoz, F., additional, Avuzzi, B., additional, Garibaldi, E., additional, Cante, D., additional, Waskiewicz, J.M., additional, Magli, A., additional, Faiella, A., additional, Villa, E., additional, Ferella, L., additional, Gatti, M., additional, Noris Chiorda, B., additional, Piva, C., additional, Ferrari, P., additional, Rancati, T., additional, Badenchini, F., additional, Girelli, G., additional, Moretti, E., additional, Valdagni, R., additional, Bresolin, A., additional, Di Muzio, N., additional, and Fiorino, C., additional

Published
2021
Full Text
View/download PDF

49. PD-0782 Predicting bRFS after salvage post-prostatectomy RT with a “one-size-fits-all” TCP-based formula

Author

Olivieri, M., primary, Magli, A., additional, Cante, D., additional, Noris Chiorda, B., additional, Munoz, F., additional, Faiella, A., additional, Olivetta, E., additional, Signor, M.A., additional, Piva, C., additional, Avuzzi, B., additional, Ferella, L., additional, Pastorino, A., additional, Broggi, S., additional, Fodor, A., additional, Deantoni, C., additional, Rancati, T., additional, Sanguineti, G., additional, Valdagni, R., additional, Di Muzio, N., additional, Cozzarini, C., additional, and Fiorino, C., additional

Published
2021
Full Text
View/download PDF

50. PO-0961 Role of depth of infiltration (DOI) as independent prognostic factor in pT1--T2 N0 oral tongue SCC

Author

Augugliaro, M., primary, Alterio, D., additional, Tagliabue, M., additional, D’urso, P., additional, Volpe, S., additional, Bruschini, R., additional, Farneti, A., additional, Marvaso, G., additional, Turturici, I., additional, Riccio, S., additional, Jereczek-Fossa, B.A., additional, Sanguineti, G., additional, and Ansarin, M., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results